0000000000181698

AUTHOR

Agata Bielecka-dabrowa

0000-0001-6666-3999

showing 4 related works from this author

Association of statin use and clinical outcomes in heart failure patients : a systematic review and meta-analysis

2019

Abstract Background The role of statins in patients with heart failure (HF) of different levels of left ventricular ejection fraction (LVEF) remains unclear especially in the light of the absence of prospective data from randomized controlled trials (RCTs) in non-ischemic HF, and taking into account potential statins’ prosarcopenic effects. We assessed the association of statin use with clinical outcomes in patients with HF. Methods We searched PubMed, EMBASE, Scopus, Google Scholar and Cochrane Central until August 2018 for RCTs and prospective cohorts comparing clinical outcomes with statin vs non-statin use in patients with HF at different LVEF levels. We followed the guidelines of the 2…

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismClinical Biochemistry610Heart failure030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled trialHeart failure; Hospitalization; Meta-analysis; Mortality; StatinslawInternal medicineHumansMedicineCardiac and Cardiovascular SystemsProspective StudiesMortalitylcsh:RC620-627Kardiologibusiness.industryResearchBiochemistry (medical)Hazard ratioStatinsmedicine.diseaseConfidence interval3. Good healthHospitalizationlcsh:Nutritional diseases. Deficiency diseasesMeta-analysisTreatment Outcome030104 developmental biologyMeta-analysisHeart failureHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCohort study
researchProduct

The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardio…

2013

Background: We assessed the influence of atorvastatin on selected indicators of an inflammatory condition, left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy (DCM). Methods. We included 68 DCM patients with left ventricular ejection fraction (LVEF) ≤40% treated optimally in a prospective, randomized study. They were observed for 5 years. Patients were divided into two groups: patients who were commenced on atorvastatin 40 mg daily for two months followed by an individually matched dose of 10 or 20 mg/day (group A), and patients who were treated according to current recommendations without statin therapy (group B). Results: After 5-year follow-u…

Cardiomyopathy DilatedMalemedicine.medical_specialtyStatinmedicine.drug_classAtorvastatinEndocrinology Diabetes and MetabolismClinical BiochemistryDiastoleCardiomyopathyDilated cardiomyopathyHemodynamicsHeart failureAtorvastatin Dilated cardiomyopathy Heart failure InflammationVentricular Function LeftEndocrinologyInternal medicinemedicineAtorvastatinHumansPyrrolescardiovascular diseasesAgedBiochemistry medicalInflammationEjection fractionbusiness.industryResearchBiochemistry (medical)Anti-Inflammatory Agents Non-SteroidalDilated cardiomyopathyMiddle Agedmedicine.diseaseUric AcidHospitalizationHeptanoic AcidsHeart failureCardiologyCytokinesFemalebusinessmedicine.drugFollow-Up StudiesLipids in health and disease
researchProduct

Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP)

2020

Abstract Acute and chronic physical exercises may enhance the development of statin-related myopathy. In this context, the recent (2019) guidelines of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) for the management of dyslipidemias recommend that, although individuals with dyslipidemia should be advised to engage in regular moderate physical exercise (for at least 30 min daily), physicians should be alerted with regard to myopathy and creatine kinase (CK) elevation in statin-treated sport athletes. However it is worth emphasizing that abovementioned guidelines, previous and recent ESC/EAS consensus papers on adverse effects of statin therapy as wel…

0301 basic medicinemedicine.medical_specialtyConsensusSports medicineContext (language use)Physical exercise03 medical and health sciences0302 clinical medicineAthlethsMuscular DiseasesStatin intoleranceMedicineHumansAdverse effectAthlethExerciseMylagiaDyslipidemiasPharmacologybiologybusiness.industryAthletesExercisesAthleths Exercises Management Mylagia Statin intolerance.Athleths; Exercises; Management; Mylagia; Statin intolerancemedicine.diseasebiology.organism_classificationManagement030104 developmental biologyAthletes030220 oncology & carcinogenesisPhysical therapyPosition paperStatin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

MOESM1 of Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis

2019

Additional file 1: Appendix 1. Assessment of risk of bias in the included studies using Cochrane criteria for RCTs. Appendix 2. Assessment of risk of bias in the included studies using Newcastle-Ottawa Quality Assessment Scale (NOS) for cohort studies. Figure S1. Association of statin versus non-statin use with all-cause mortality in heart failure only in cohort studies. Figure. S2. Association of statin versus non-statin use with CV mortality in heart failure only in cohort studies. Figure S3. Association of statin versus non-statin use hospitalization in heart failure only in cohort studies. Figure S4. Association of statin versus non-statin use with all-cause mortality by type of heart f…

nutritional and metabolic diseaseslipids (amino acids peptides and proteins)cardiovascular diseases
researchProduct